
TELA Stock Forecast & Price Target
TELA Analyst Ratings
Bulls say
TELA Bio Inc. has demonstrated significant growth potential, evidenced by a 22% increase in OviTex unit sales and a 3% rise in OviTex PRS unit sales for the quarter, alongside a sequential revenue improvement of 2% despite facing leadership transitions. The company's recent financial maneuvers, including a $13 million equity raise and an upsizing of debt capacity, have enhanced its cash runway, positioning it well for continued investment in sales force expansion and product development as it targets over 90 territory managers by early 2026. Furthermore, TELA's structured approach to improving productivity and establishing an achievable sales growth floor for 2026 indicates a commitment to sustainable growth amid a recalibrated outlook, reinforcing a positive trajectory for the company's financial performance.
Bears say
TELA Bio Inc. has reduced its revenue guidance for 2025, projecting at least 16% growth year-over-year, which translates to a minimum of $80.4 million, down from previous expectations of $85.0 million to $88.0 million reflecting a growth rate of 23-27%. The company also indicated early projections for 2026 growth at a minimum of 15%, further signaling a slowdown in anticipated revenue growth. Additionally, while operating expenses were lower than expected, the gross margin of 67.5% fell short of targets by 200 basis points and represented a decline compared to previous periods, contributing to a missed operating income target and reflecting broader operational challenges.
This aggregate rating is based on analysts' research of TELA Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.
TELA Analyst Forecast & Price Prediction
Start investing in TELA
Order type
Buy in
Order amount
Est. shares
0 shares